A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-396 and Co-administration of CKD-501 and D759 in Healthy Adults
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Lobeglitazone (Primary) ; Lobeglitazone/sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
Most Recent Events
- 14 Feb 2020 New trial record